RxDoctor Payments Data

Shireen Moore, MD

Family Medicine · Evans, GANPI 1003042805

Payments from drug & device makers

$1,373in general payments, 2019–2025

Across 83 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$417
  • AbbVie$306
  • Abbott$122
  • Lilly USA, LLC$88
  • Pfizer$77
  • Corcept Therapeutics$40
  • plus $324 from 16 others

What the payments were for

  • Food & beverage$1,27793%
  • Education$977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,373 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$303,903
Medicare patients
395
Services billed
7,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$279,400
MounjaroTirzepatide87$131,627
EliquisApixaban65$73,773
JardianceEmpagliflozin42$55,870
FarxigaDapagliflozin Propanediol44$52,208
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$51,166
RybelsusSemaglutide26$49,249
LinzessLinaclotide21$29,384
MyrbetriqMirabegron20$23,268
WegovySemaglutide15$19,102
TrulicityDulaglutide14$16,193
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$15,599
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,366
Combivent RespimatIpratropium/Albuterol Sulfate15$9,075
ShingrixVaricella-Zoster Ge/As01b/Pf40$8,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$417$347,751237 claims
Lilly USA, LLCMounjaro, Trulicity$88$147,820101 claims
PfizerEliquis, Paxlovid$77$76,631109 claims
GSKTrelegy Ellipta, Shingrix$29$60,07691 claims
AstraZenecaFarxiga$15$52,20844 claims
AbbVieLinzess, Synthroid$306$38,269123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →